The Food and Drug Administration recently approved the Adacel (Tdap) vaccine to be administered as soon as 8 years after a previous dose. Adacel, manufactured by Sanofi Pasteur, provides immunity to tetanus, diphtheria, and pertussis. The vaccine is approved for patients ages 10-64, and is available in a syringe made without natural rubber latex.
The current CDC recommendations for Tdap are as follows:
- Adolescents should receive a single dose, preferably at age 11 or 12
- All pregnant women should receive a single dose during pregnancy, preferably between weeks 27 and 36. By receiving this vaccine, pregnant mothers pass antibodies to their babies, reducing the risk of whooping cough.
- Adults should receive a single dose of Tdap followed by a booster Td every 10 years.
FDA approval was based on clinical data from a study that showed no significant differences in adverse events when adults received Adacel versus Td 8-12 years after a previous dose of Adacel. The approval of Adacel administration every 8 years provides more flexibility for physicians in both vaccine purchasing decisions and immunizations scheduling. Sanofi has provided study results to the CDC for consideration in future recommendations.